Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Zepbound (Tirzepatide) Vomiting: Diet Protocols That Help

By
Published Updated Last reviewed
3 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Vomiting rate / 8% (5 mg), 11% (10 mg), 13% (15 mg) vs 2% placebo [1]
  • Usual timing / During dose escalation, decreasing over time [1]
  • Any GI adverse reaction / 56% on every Zepbound dose vs 30% placebo [1]
  • Stopped for GI reasons / 1.9% (5 mg), 3.3% (10 mg), 4.3% (15 mg) vs 0.5% placebo [1]
  • Label escalation / 2.5 mg for 4 weeks, then 2.5 mg steps at least 4 weeks apart [1]
  • Ginger / 1,500 mg daily in divided doses eased nausea in GI trials [2]
  • Peppermint oil / Placebo-controlled trials support it for post-operative nausea [3]
  • Dehydration / The label says to monitor renal function if reactions could cause volume loss [1]

How often does vomiting happen on Zepbound?

In the label's two pooled placebo-controlled weight-management trials, 958 people received placebo and 630, 948 and 941 received 5, 10 and 15 mg [1]. Vomiting was reported by 2% on placebo versus 8%, 11% and 13% on the three doses; nausea by 8% versus 25%, 29% and 28% [1]. Any gastrointestinal adverse reaction occurred in 56% of people on every Zepbound dose versus 30% on placebo, and 1.9%, 3.3% and 4.3% stopped treatment for gastrointestinal reasons versus 0.5% on placebo [1]. Severe gastrointestinal reactions were reported in 1.7%, 2.5% and 3.1% versus 1%, and the label says Zepbound is not recommended in people with severe gastroparesis [1].

What the label says about the dose schedule

The label's own lever on gastrointestinal reactions is the escalation schedule: 2.5 mg once weekly for 4 weeks as an initiation dose, then 2.5 mg steps after at least 4 weeks on the current dose, a schedule the label ties to reducing the risk of gastrointestinal adverse reactions [1]. If a maintenance dose is not tolerated, the label says to consider a lower maintenance dose [1].

Ginger and peppermint: what the evidence covers

A 2019 systematic review of clinical trials in gastrointestinal disorders concluded that a divided daily dose of 1,500 mg of ginger is beneficial for nausea relief [2]. A 2018 review found placebo-controlled trials supporting peppermint oil for irritable bowel syndrome, functional dyspepsia, childhood functional abdominal pain and post-operative nausea, with few adverse effects reported in trials [3]. Both bodies of evidence come from settings other than tirzepatide treatment.

Dehydration and other label warnings

The label describes postmarketing reports of acute kidney injury, sometimes requiring hemodialysis, in people on GLP-1 receptor agonists or Zepbound, with the majority of reported events in patients who had gastrointestinal reactions leading to dehydration such as nausea, vomiting or diarrhea, and it advises monitoring renal function in patients reporting reactions that could lead to volume depletion, especially during initiation and dose escalation [1]. The label also lists acute pancreatitis, which may include persistent or severe abdominal pain sometimes radiating to the back and may or may not be accompanied by nausea or vomiting, and says to discontinue Zepbound and start appropriate management if pancreatitis is suspected [1].

Frequently asked questions

Which foods help with Zepbound vomiting?
The Zepbound label names none. Ginger, at 1,500 mg daily in divided doses, eased nausea in gastrointestinal disorders [2], and peppermint oil has placebo-controlled support in post-operative nausea [3]. Both were studied outside tirzepatide use.
How long does Zepbound vomiting last?
The label reports that the majority of nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time [1]. It does not describe a fixed duration for an individual.
Should I take Zepbound with food?
The label allows Zepbound at any time of day, with or without food [1].
What does the label say about a lower dose?
The label states that if patients do not tolerate a maintenance dose, a lower maintenance dose should be considered [1]. The approved maintenance doses for weight reduction are 5 mg, 10 mg and 15 mg once weekly [1].
Which label warnings involve vomiting?
The label lists acute pancreatitis, which may include persistent or severe abdominal pain sometimes radiating to the back and may or may not be accompanied by nausea or vomiting, and says to discontinue Zepbound and start appropriate management if pancreatitis is suspected [1]. It also advises monitoring renal function in patients reporting reactions that could lead to volume depletion, especially during initiation and dose escalation [1].

References

  1. U.S. National Library of Medicine, DailyMed. Zepbound injection (tirzepatide) prescribing information. Zepbound injection (tirzepatide) label
  2. Nikkhah Bodagh M, Maleki I, Hekmatdoost A. Ginger in gastrointestinal disorders: A systematic review of clinical trials. Food Sci Nutr. 2019;7(1):96-108. Ginger in gastrointestinal disorders: A systematic review of clinical trials
  3. Chumpitazi BP, Kearns GL, Shulman RJ. Review article: the physiological effects and safety of peppermint oil and its efficacy in irritable bowel syndrome and other functional disorders. Aliment Pharmacol Ther. 2018;47(6):738-752. Review article: the physiological effects and safety of peppermint oil and its efficacy in irritable bowel syndrome and other functional disorders
Evidence overview for Zepbound (Tirzepatide) Vomiting: Diet Protocols That Help